| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10005292 | HBV | ENSG00000151726.16 | protein_coding | ACSL1 | No | No | 2180 | E7EPM6 P33121 |
| TVIS10005142 | HBV | ENSG00000151726.16 | protein_coding | ACSL1 | No | No | 2180 | E7EPM6 P33121 |
| TVIS10005143 | HBV | ENSG00000151726.16 | protein_coding | ACSL1 | No | No | 2180 | E7EPM6 P33121 |
| TVIS10004200 | HBV | ENSG00000151726.16 | protein_coding | ACSL1 | No | No | 2180 | E7EPM6 P33121 |
| TVIS10029860 | HBV | ENSG00000151726.16 | protein_coding | ACSL1 | No | No | 2180 | E7EPM6 P33121 |
| TVIS10060173 | HBV | ENSG00000151726.16 | protein_coding | ACSL1 | No | No | 2180 | E7EPM6 P33121 |
| TVIS10060174 | HBV | ENSG00000151726.16 | protein_coding | ACSL1 | No | No | 2180 | E7EPM6 P33121 |
| TVIS10060172 | HBV | ENSG00000151726.16 | protein_coding | ACSL1 | No | No | 2180 | E7EPM6 P33121 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ACSL1 |
|---|---|
| DrugBank ID | DB00131 |
| Drug Name | Adenosine phosphate |
| Target ID | BE0000639 |
| UniProt ID | P33121 |
| Regulation Type | product of |
| PubMed IDs | 16981708; 17350930 |
| Citations | Ingram-Smith C, Woods BI, Smith KS: Characterization of the acyl substrate binding pocket of acetyl-CoA synthetase. Biochemistry. 2006 Sep 26;45(38):11482-90.@@Ingram-Smith C, Smith KS: AMP-forming acetyl-CoA synthetases in Archaea show unexpected diversity in substrate utilization. Archaea. 2007 May;2(2):95-107. |
| Groups | Approved; Investigational; Nutraceutical; Withdrawn |
| Direct Classification | Purine ribonucleoside monophosphates |
| SMILES | NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC=N1 |
| Pathways | Leigh Syndrome; Histidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); Fatty Acid Metabolism; Gentamicin Action Pathway; Pyruvate Dehydrogenase Complex Deficiency; Purine Nucleoside Phosphorylase Deficiency; Hyperprolinemia Type II; Glutamate Metabolism; Clarithromycin Action Pathway; Argininosuccinic Aciduria; Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency); Hyperinsulinism-Hyperammonemia Syndrome; Butyrate Metabolism; Pyruvate Metabolism; Pentose Phosphate Pathway; Propanoate Metabolism; Glycine and Serine Metabolism; Selenoamino Acid Metabolism; Thiamine Metabolism; Oxytetracycline Action Pathway; Tetracycline Action Pathway; Carbamoyl Phosphate Synthetase Deficiency; Hyperprolinemia Type I; Histidine Metabolism; Cystathionine beta-Synthase Deficiency; Arginine and Proline Metabolism; Roxithromycin Action Pathway; Purine Metabolism; Ammonia Recycling |
| PharmGKB | PA164744376 |
| ChEMBL | CHEMBL752 |
